ALPA vs THEMISMED: Stock Comparison

Alpa Laboratories Limited vs Themis Medicare Limited

Live data: 22 July 2026, 2:57 PM IST • Source: NSE and company filings

Themis Medicare Limited is the larger company by market capitalisation. Alpa Laboratories Limited shows a lower P/E, a higher ROE and lower leverage, while Themis Medicare Limited shows a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Alpa Laboratories Limited and Themis Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ALPA is more favourable on 8 of 13 scored metrics and THEMISMED on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
THEMISMED is the larger company
₹1,004 Cr vs ₹142 Cr
P/E Ratio
ALPA has a lower P/E
12.09x vs 938.33x
P/B Ratio
ALPA has a lower P/B
0.77x vs 2.6x
EPS
ALPA has higher earnings per share
₹7.14 vs ₹0.12
Dividend Yield
THEMISMED has a higher dividend yield
0.43% vs 0%
Revenue Growth (TTM YoY)
THEMISMED has faster revenue growth
6.7% vs -21.4%
Qtr Sales Growth
THEMISMED has stronger quarterly sales growth
6.74% vs -21.3%
Qtr Profit Growth
THEMISMED has stronger quarterly profit growth
192% vs 165%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricALPATHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricALPATHEMISMED
Live Price₹66.98₹108.06
Day Change-0.98%-3.82%
Volume6,95870,642
52-Week High₹105.51₹148
52-Week Low₹46.1₹64.95
Distance from 52W High-36.52%-26.99%

Valuation

MetricALPATHEMISMED
Market Cap₹142 Cr₹1,004 Cr
P/E Ratio12.09x938.33x
P/B Ratio0.77x2.6x
EPS₹7.14₹0.12
Book Value₹32.34₹43.06
Dividend Yield0%0.43%

Growth

MetricALPATHEMISMED
Revenue Growth (TTM YoY)-21.4%6.7%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-21.3%6.74%
Qtr Profit Growth165%192%

Profitability & Leverage

MetricALPATHEMISMED
ROE8.39%0.29%
ROCE9.42%2.74%
Net Margin14.33%0.33%
Operating Margin3.11%-2.9%
Debt to Equity0.01x25.11x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricALPATHEMISMED
Promoter Holding57.19%57.5%
FII Holding0.35% 0.03 pp0.11% 0.06 pp
DII Holding0.07% 0.07 pp0.01%
Public Holding42.39% 0.04 pp32.78% 0.05 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alpa Laboratories Limited and Themis Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.